摘要
目的:观察参芪扶正注射液联合多西他赛加洛铂治疗老年中晚期肺癌的疗效和毒副反应。方法:将63例非小细胞肺癌(NSCLC)中晚期老年患者随机分为2组。其中对照组31例,单纯使用多西他赛加洛铂化疗;观察组32例,使用多西他赛加洛铂化疗,同时给予参芪扶正注射液。在治疗2个周期时评价2组的疗效和毒副反应。结果:2组的近期疗效无明显统计学差异,观察组生活质量的提高和中医症候改善的有效率优于对照组(P<0.05,P<0.01),对照组的中性粒细胞减少、ALT升高及乏力等毒副反应则多于观察组(P<0.05或P<0.01)。结论:参芪扶正注射液联合多西他赛加洛铂可明显改善老年中晚期肺癌患者的临床症状和生活质量,减少患者化疗的毒副反应。
Objective:To observe the treatment effects and the toxicant-side reactions of the shenqi fuzheng injection (参芪扶正注射液) combing the docetaxel and lobaplatin in treatment of old middle-advanced stage lung cancer. Methods : 63 cases of the old patients with the non-small cell lung cancer ( NSCLC ) of middle-advanced stage were divided into two groups at random. The control group is 31 cases and they only were treated by chemotherapy used the docetaxel and loba- platin. The observation group is 32 cases and they were treated by chemotherapy used the docetaxel and lobaplatin com- bined with shenqi fuzheng injection in same time. The treatment effects and the toxicant-side reactions of two groups were evaluated when treatment is two periods. Results : The short-term curative effects of two groups have not obvious statisti- cal difference. The increase of lived quality and the total efficient rate of syndrome improvement for the observation group apparently are superior to the control group (P〈0.05 and P〈0.01 ). The toxicant-side reactions such as the decrease of neutrophil, the increase of alanine transaminase ( ALT ) and the weakness for the control group apparently are many to the observation group (P〈0.05 or P〈0.01 ). Conclusions :The shenqi fuzheng injection combing the docetaxel and lobaplatin may obviously improve the clinical symptoms and the lived quality of old patients with middle-advanced stage lung cancer and reduce the toxicant-side reactions of these patients when the chemotherapy.
出处
《中医药临床杂志》
2015年第5期676-679,共4页
Clinical Journal of Traditional Chinese Medicine
关键词
参芪扶正注射液
多西他赛
洛铂
老年患者
非小细胞肺癌
Shenqi fuzheng injection
Docetaxel
Lobaplatin
Old patient
Non'small cell lung cancer